Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors

Soft tissue and bone sarcomas represent a group of aggressive neoplasms often accompanied by dismal patient prognosis, especially when distant metastases are present. Moreover, effective treatment can pose a challenge, as recurrences are frequent and almost half of patients present with advanced dis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Argyris C. Hadjimichael, Alexandros Pergaris, Angelos Kaspiris, Athanasios F. Foukas, Stamatios E. Theocharis
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	liquid biopsy soft tissue sarcomas bone sarcomas biomarkers cancer diagnosis Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/d790488bd526459ab57ce3d7d2a52854
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d790488bd526459ab57ce3d7d2a52854
record_format	dspace
spelling	oai:doaj.org-article:d790488bd526459ab57ce3d7d2a528542021-11-11T16:59:08ZLiquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors10.3390/ijms2221115261422-00671661-6596https://doaj.org/article/d790488bd526459ab57ce3d7d2a528542021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11526https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Soft tissue and bone sarcomas represent a group of aggressive neoplasms often accompanied by dismal patient prognosis, especially when distant metastases are present. Moreover, effective treatment can pose a challenge, as recurrences are frequent and almost half of patients present with advanced disease. Researchers have unveiled the molecular abnormalities implicated in sarcomas’ carcinogenesis, paving the way for novel treatment strategies based on each individual tumor’s characteristics. Therefore, the development of new techniques aiding in early disease detection and tumor molecular profiling is imperative. Liquid biopsy refers to the sampling and analysis of patients’ fluids, such as blood, to identify tumor biomarkers, through a variety of methods, including qRT-PCR, qPCR, droplet digital PCR, magnetic microbeads and digital PCR. Assessment of circulating tumor cells (CTCs), circulating free DNA (ctDNA), micro RNAs (miRs), long non-coding RNAs (lncRNAs), exosomes and exosome–associated proteins can yield a plethora of information on tumor molecular signature, histologic type and disease stage. In addition, the minimal invasiveness of the procedure renders possible its wide application in the clinical setting, and, therefore, the early detection of the presence of tumors. In this review of the literature, we gathered information on biomarkers assessed through liquid biopsy in soft tissue and bone sarcoma patients and we present the information they can yield for each individual tumor type.Argyris C. HadjimichaelAlexandros PergarisAngelos KaspirisAthanasios F. FoukasStamatios E. TheocharisMDPI AGarticleliquid biopsysoft tissue sarcomasbone sarcomasbiomarkerscancerdiagnosisBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11526, p 11526 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liquid biopsy soft tissue sarcomas bone sarcomas biomarkers cancer diagnosis Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	liquid biopsy soft tissue sarcomas bone sarcomas biomarkers cancer diagnosis Biology (General) QH301-705.5 Chemistry QD1-999 Argyris C. Hadjimichael Alexandros Pergaris Angelos Kaspiris Athanasios F. Foukas Stamatios E. Theocharis Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
description	Soft tissue and bone sarcomas represent a group of aggressive neoplasms often accompanied by dismal patient prognosis, especially when distant metastases are present. Moreover, effective treatment can pose a challenge, as recurrences are frequent and almost half of patients present with advanced disease. Researchers have unveiled the molecular abnormalities implicated in sarcomas’ carcinogenesis, paving the way for novel treatment strategies based on each individual tumor’s characteristics. Therefore, the development of new techniques aiding in early disease detection and tumor molecular profiling is imperative. Liquid biopsy refers to the sampling and analysis of patients’ fluids, such as blood, to identify tumor biomarkers, through a variety of methods, including qRT-PCR, qPCR, droplet digital PCR, magnetic microbeads and digital PCR. Assessment of circulating tumor cells (CTCs), circulating free DNA (ctDNA), micro RNAs (miRs), long non-coding RNAs (lncRNAs), exosomes and exosome–associated proteins can yield a plethora of information on tumor molecular signature, histologic type and disease stage. In addition, the minimal invasiveness of the procedure renders possible its wide application in the clinical setting, and, therefore, the early detection of the presence of tumors. In this review of the literature, we gathered information on biomarkers assessed through liquid biopsy in soft tissue and bone sarcoma patients and we present the information they can yield for each individual tumor type.
format	article
author	Argyris C. Hadjimichael Alexandros Pergaris Angelos Kaspiris Athanasios F. Foukas Stamatios E. Theocharis
author_facet	Argyris C. Hadjimichael Alexandros Pergaris Angelos Kaspiris Athanasios F. Foukas Stamatios E. Theocharis
author_sort	Argyris C. Hadjimichael
title	Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
title_short	Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
title_full	Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
title_fullStr	Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
title_full_unstemmed	Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors
title_sort	liquid biopsy: a new translational diagnostic and monitoring tool for musculoskeletal tumors
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d790488bd526459ab57ce3d7d2a52854
work_keys_str_mv	AT argyrischadjimichael liquidbiopsyanewtranslationaldiagnosticandmonitoringtoolformusculoskeletaltumors AT alexandrospergaris liquidbiopsyanewtranslationaldiagnosticandmonitoringtoolformusculoskeletaltumors AT angeloskaspiris liquidbiopsyanewtranslationaldiagnosticandmonitoringtoolformusculoskeletaltumors AT athanasiosffoukas liquidbiopsyanewtranslationaldiagnosticandmonitoringtoolformusculoskeletaltumors AT stamatiosetheocharis liquidbiopsyanewtranslationaldiagnosticandmonitoringtoolformusculoskeletaltumors
_version_	1718432206820474880

Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors

Ejemplares similares